Brett Loop
Novartis (Switzerland)(CH)Novartis (United States)(US)Pharmac(NZ)
Publications by Year
Research Areas
Cystic Fibrosis Research Advances, Chronic Lymphocytic Leukemia Research, Migraine and Headache Studies, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research
Most-Cited Works
- → Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data(2021)57 cited
- → Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials(2022)21 cited
- → Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions(2022)9 cited
- → Inpatient Constipation Among Migraine Patients Prescribed Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database(2022)4 cited
- → Diagnosed cataracts in patients with cystic fibrosis in a United States administrative database(2017)3 cited
- → Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a Phase 3, randomised, controlled trial (EXPAND)(2019)2 cited
- → Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)(2019)2 cited
- → Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis(2023)1 cited
- → S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE)(2018)1 cited
- → PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACAFTOR/IVACAFTOR (TEZ/IVA)(2018)1 cited